James Frates Joins Amylyx Pharmaceuticals as Chief Financial Officer
January 14, 2021
- Former Alkermes Chief Financial Officer Expands Amylyx Executive Leadership Team as the Company Grows and Scales Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease ...
Read More
Amylyx Pharmaceuticals Appoints Erin Whitney Head of Global Clinical Operations, Shauna Horvath Head of Global Marketing and Keith White Head of Global Market Access
December 21, 2020
Amylyx Continues to Expand Leadership Team to Support Clinical Development and Commercial Growth Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative ...
Read More
Amylyx Pharmaceuticals to Present Positive Functional and Survival Data and New Predictive Modeling Results from the CENTAUR Trial in People with ALS at the 31st International Symposium on ALS/MND
December 9, 2020
- Administration of AMX0035 Is Associated with a Statistically Significant Retention of Functional Abilities and Long-Term Survival Benefit in People Living with ALS - New Analysis Using ENCALS Survival Prediction Model Demonstrates Longer Overall Survival Resulting ...
Read More
Amylyx Pharmaceuticals Announces FDA Granted Orphan Drug Designation for AMX0035 for the Treatment of Wolfram Syndrome
November 16, 2020
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Read More
Amylyx Pharmaceuticals Announces Last Patient Completes Final Study Visit in PEGASUS Trial of AMX0035 in Alzheimer’s Disease
November 9, 2020
Topline Results Expected in the First Half of 2021 Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that the ...
Read More
Amylyx Pharmaceuticals Announces Publication of CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS
October 16, 2020
Data From CENTAUR Trial Published in Muscle & Nerve Demonstrates That Administration of AMX0035 Results in Longer Survival for People With ALS Early Administration of AMX0035 Reduced the Risk of Death by 44% Over the Duration ...
Read More
Amylyx Pharmaceuticals Highlights New Long-Term Safety Data from CENTAUR Study of AMX0035 in People with ALS at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2020 Virtual Meeting
October 9, 2020
Data from New Long-Term Safety Analysis Show No New Safety Concerns with AMX0035 Identified in the Open-Label Extension Study Data Were Consistent with Primary Outcome of Statistically Significant Slowing of the Functional Decline Associated with ...
Read More
Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020
September 28, 2020
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that it has been named by Fierce Biotech as one ...
Read More
Amylyx Pharmaceuticals Announces New England Journal of Medicine Publication of Pivotal AMX0035 Data Demonstrating Statistically Significant Benefit in People with ALS
September 2, 2020
- Patients Retained Function Longer on AMX0035 Versus Placebo; Study Achieved Its Primary Outcome of a Difference on the Revised ALS Functional Rating Scale - AMX0035 is the First Investigational Therapy to Demonstrate Statistically Significant Benefit ...
Read More
Tammy Sarnelli Joins Amylyx Pharmaceuticals as Global Head of Regulatory Affairs
August 25, 2020
Former Biogen and EMD Serono Executive with Broad Experience in the Neurology and Rare Disease Space Bolsters Growing Amylyx Executive Leadership Team Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic ...
Read More
Amylyx Pharmaceuticals Raises $30 Million in Series B Funding
July 1, 2020
- Proceeds enable continued investment in lead product candidate AMX0035 in ALS and Alzheimer’s disease - Amylyx has closed more than $45M in financing in 2020 Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new ...
Read More
Amylyx Pharmaceuticals Announces Completion of Enrollment in the PEGASUS Trial of AMX0035 in Alzheimer’s Disease
June 15, 2020
- Amylyx Remains on Track to Share Topline PEGASUS Trial Results by Q1 2021 Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, ...
Read More
Machelle Manuel, Ph.D., Joins Amylyx Pharmaceuticals as Vice President, Head of Global Medical Affairs
May 11, 2020
New Vice President of Medical Affairs Brings 20+ Years of Experience to Growing Leadership Team Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today ...
Read More
Amylyx Pharmaceuticals Gets #INKEDforALS
May 4, 2020
Company Launches #INKEDforALS Campaign in its Commitment to Raising Awareness for the ALS Community During ALS Awareness Month Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and ...
Read More
European Medicines Agency Grants Orphan Drug Designation to Amylyx Pharmaceuticals’ AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
April 29, 2020
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has ...
Read More
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial
December 17, 2019
Study Meets Primary Endpoint of Slowing of ALS as Measured by the ALSFRS-R Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the ...
Read More
Amylyx Announces Appointment of Debra Canner as Global Head of Human Resources
December 12, 2019
Passionate HR Leader Brings 20+ Years of Experience to Solidify the Growth of the Company’s Team CAMBRIDGE, Mass. (BUSINESS WIRE) –Amylyx Pharmaceuticals, Inc., today announced the appointment of Debra Canner as the company’s first ...
Read More
Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS
October 4, 2019
CAMBRIDGE, Mass. ( BUSINESS WIRE) –Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the ...
Read More
Amylyx Pharmaceuticals Strengthens Leadership Team with the Appointments of Chief Medical Officer, Chief Commercial Officer and Global Head, Supply Chain
June 24, 2019
CAMBRIDGE, MA ( BUSINESS WIRE ) — Amylyx Pharmaceuticals, Inc., today announced three additions to its executive leadership team, appointing industry veterans Patrick Yeramian, M.D., MBA, as chief medical officer, Margaret Olinger, MBA, as chief commercial ...
Read More
Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
April 3, 2019
CAMBRIDGE, MA ( BUSINESS WIRE ) — Amylyx Pharmaceuticals, Inc., in collaboration with the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Cure Alzheimer’s Fund, today announced the dosing of its ...
Read More